Published in J Immunol on November 01, 2000
Prevention of arthritis by interleukin 10-producing B cells. J Exp Med (2003) 4.27
Identification of regulatory T cells in tolerated allografts. J Exp Med (2002) 3.60
Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med (2005) 3.17
Langerhans cells are not required for efficient skin graft rejection. J Invest Dermatol (2008) 2.41
Tregs and transplantation tolerance. J Clin Invest (2004) 1.49
GITR Blockade Facilitates Treg Mediated Allograft Survival. Transplantation (2009) 1.48
Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med (2011) 1.43
Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol (2007) 1.34
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
TGFbeta1 and Treg cells: alliance for tolerance. Trends Mol Med (2007) 1.30
The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res (2009) 1.25
CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest (2007) 1.23
Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol (2009) 1.21
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest (2002) 1.12
Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr Rev (2008) 1.12
Retinoic acid in the immune system. Ann N Y Acad Sci (2008) 1.09
Transplantation tolerance: lessons from experimental rodent models. Transpl Int (2007) 0.94
Regulation and privilege in transplantation tolerance. J Clin Immunol (2008) 0.93
Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One (2010) 0.92
Homeostatic T cell proliferation as a barrier to T cell tolerance. Philos Trans R Soc Lond B Biol Sci (2005) 0.91
Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol (2012) 0.91
The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci (2011) 0.87
Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models. Front Immunol (2013) 0.86
Long-term control of alloreactive B cell responses by the suppression of T cell help. J Immunol (2008) 0.83
Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. Immunol Rev (2008) 0.83
TGF-beta, T-cell tolerance and anti-CD3 therapy. Trends Mol Med (2004) 0.82
CD154 blockade abrogates allospecific responses and enhances CD4(+) regulatory T-cells in mouse orthotopic lung transplant. Am J Transplant (2011) 0.81
T cell tolerance induced by therapeutic antibodies. Philos Trans R Soc Lond B Biol Sci (2005) 0.81
Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. J Clin Invest (2002) 0.80
CD4-blockade can induce protection from peanut-induced anaphylaxis. Front Immunol (2011) 0.79
The role of T helper cell differentiation in promoting nerve allograft survival with costimulation blockade. J Neurosurg (2010) 0.79
Update on CD40 and CD154 blockade in transplant models. Immunotherapy (2015) 0.78
Glucocorticoid-induced TNFR-related protein stimulation reverses cardiac allograft acceptance induced by CD40-CD40L blockade. Clin Dev Immunol (2013) 0.77
Regulatory T cells and the control of the allergic response. J Allergy (Cairo) (2012) 0.77
IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice. J Korean Med Sci (2006) 0.77
Ursolic acid promotes robust tolerance to cardiac allografts in mice. Clin Exp Immunol (2011) 0.76
Transplantation: focus on kidney, liver and islet cells. Can J Surg (2004) 0.75
The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4(+) T cells. Front Immunol (2017) 0.75
Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype. J Biomed Biotechnol (2012) 0.75
Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance. Front Immunol (2015) 0.75
Viral infection: a potent barrier to transplantation tolerance. Clin Dev Immunol (2008) 0.75
Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts. Springer Semin Immunopathol (2004) 0.75
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
"Infectious" transplantation tolerance. Science (1993) 4.98
Reshaping human antibodies for therapy. Nature (1988) 4.82
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Metabolism of proline and the hydroxyprolines. Annu Rev Biochem (1980) 2.91
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Mapping quantitative trait loci for murine growth: a closer look at genetic architecture. Genet Res (1999) 2.27
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature (1986) 2.25
IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol (2000) 2.04
Letter: T cell-dependent mediator in the immune response. Nature (1973) 1.94
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Induction of classical transplantation tolerance in the adult. J Exp Med (1989) 1.91
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. Br J Cancer (1967) 1.88
Breakdown of self-tolerance in anergic B lymphocytes. Nature (1991) 1.87
Limiting dilution analysis of helper T-cell function. Immunology (1975) 1.82
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol (1990) 1.79
Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis (1984) 1.78
The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 1.78
Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 1.77
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant (1994) 1.76
Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 1.72
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 1.69
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation (1999) 1.67
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum (2001) 1.67
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM (1996) 1.66
Reproduction of radiologic images on plain paper. Radiographics (1998) 1.65
T cell-dependent mediator in the immune response. II. Physical and biological properties. Immunology (1974) 1.65
The influence of the major histocompatibility complex on the function of T-helper cells in antibody formation. Immunol Rev (1978) 1.64
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 1.63
Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol (2000) 1.60
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Induction of tolerance by monoclonal antibody therapy. Nature (1986) 1.53
Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab (2001) 1.52
Cooperation across the histocompatibility barrier. Nature (1975) 1.51
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol (1999) 1.50
Conditions determining the generation and expression of T helper cells. Immunol Rev (1977) 1.49
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. Immunology (1976) 1.49
Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation (1986) 1.49
Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells. Int J Cancer (1975) 1.48
Self tolerance is H-2-restricted. Nature (1984) 1.47
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J (1993) 1.46
T cell suppression in transplantation tolerance through linked recognition. J Immunol (1996) 1.45
Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. J Immunol (1997) 1.44
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol (1993) 1.44
Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. Cytotherapy (2004) 1.42
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 1.40
The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. Immunol Rev (2001) 1.40
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 1.40
Infectious tolerance. Curr Opin Immunol (1998) 1.39
T cell-dependent mediator in the immune response. III. The role of non-specific factor (NSF) in the in vitro immune response. Immunology (1975) 1.39
Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 1.39
Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation. Bone Marrow Transplant (1997) 1.39
The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol (1990) 1.39
Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A (2001) 1.38
A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. J Immunol Methods (1981) 1.38
Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol (1985) 1.37
Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol (1985) 1.34
Do L3T4+ T cells act as effector cells in protection against influenza virus infection. Immunology (1987) 1.33
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. J Exp Med (1992) 1.33
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med (1990) 1.32
Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 1.31
Sequence and immunogenicity of the 70-kDa heat shock protein of Mycobacterium leprae. J Immunol (1991) 1.31
CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol (1987) 1.31
Coenzyme content of purified alanine racemase from Pseudomonas. Biochem Biophys Res Commun (1969) 1.30
Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev (1992) 1.27
A role for CD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20 krad-irradiated and Ro 11-3128-terminated infections. Immunology (1989) 1.27
Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol (1998) 1.26